Abcellera Biologics Inc represents a commitment to cutting-edge biotechnology and scientific innovation. The company values include excellence, integrity, and collaboration. Abcellera embraces a customer-centric approach, striving to deliver solutions that advance health and well-being. Their corporate philosophy emphasizes the importance of transformative research, driving breakthroughs in drug discovery and development. With a focus on antibody therapeutics, Abcellera aims to push boundaries and revolutionize the treatment landscape for various diseases. By combining technology, data analysis, and the expertise of their diverse team, Abcellera Biologics Inc strives to make a lasting impact in the field of biopharmaceuticals.

Abcellera Biologics Inc is primarily present in Canada and the United States.

Abcellera Biologics Inc has achieved significant milestones within the biotechnology industry. The company successfully went public in December 2020, raising substantial funds to support its research and development efforts. Abcellera is renowned for its revolutionary antibody discovery platform, which played a crucial role in the development of therapies for various diseases, including COVID-19. The company formed essential partnerships with leading pharmaceutical firms, such as Eli Lilly, to expedite the production and distribution of monoclonal antibody treatments. Abcellera's groundbreaking AI-driven approach and its contributions to advancing biotherapeutics have positioned it as a key player in the field.

Abcellera Biologics Inc is a leading biotechnology company specializing in antibody discovery. Founded in 2012, Abcellera has emerged as a key player in the field of therapeutic antibody development. The company utilizes a powerful technology platform that combines high-throughput single-cell analysis, microfluidics, and genomics to rapidly identify and develop antibodies for various diseases, including infectious diseases and cancer. Abcellera has formed strategic partnerships with renowned pharmaceutical companies and research institutions, enabling them to accelerate the discovery and development of new therapies. With its innovative approach and cutting-edge technology, Abcellera Biologics Inc continues to make significant contributions to the field of biotechnology and healthcare.

The main competitors of Abcellera Biologics Inc in the market are companies such as Regeneron Pharmaceuticals, Eli Lilly and Company, and Gilead Sciences.

Abcellera Biologics Inc is primarily active in the biotechnology industry.

The business model of Abcellera Biologics Inc revolves around advancing the discovery of new antibody therapies through their innovative platform. Abcellera utilizes advanced technologies, including artificial intelligence and high-throughput single-cell screening, to identify and analyze antibodies from natural immune systems. This enables them to rapidly discover high-quality antibody candidates for various diseases, including infectious diseases and cancer. Abcellera then partners with biotechnology and pharmaceutical companies to co-develop these antibodies into potential therapies. By leveraging their robust technology and collaborative approach, Abcellera aims to accelerate the development of novel antibody-based treatments for improved patient outcomes.

pages_aktie_[isin]__12

pages_aktie_[isin]__15

pages_aktie_[isin]__18

pages_aktie_[isin]__21

pages_aktie_[isin]__24

pages_aktie_[isin]__27

pages_aktie_[isin]__30

pages_aktie_[isin]__34

pages_aktie_[isin]__36

pages_aktie_[isin]__38

pages_aktie_[isin]__40

pages_aktie_[isin]_[key]_index_1

pages_aktie_[isin]_[key]_index_3

pages_aktie_[isin]_[key]_index_5

pages_aktie_[isin]_[key]_index_7

pages_aktie_[isin]_[key]_index_9

pages_aktie_[isin]_[key]_index_14

pages_aktie_[isin]_[key]_index_15

pages_aktie_[isin]_[key]_index_18

pages_aktie_[isin]_[key]_index_20

pages_aktie_[isin]_[key]_index_22